Updated on 10 September 2012
Dacomitinib is an oral, once-daily, small molecule inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. It is being evaluated by Pfizer in a comprehensive clinical development program that includes two global, randomized phase III clinical trials investigating its safety and efficacy as a second-line and refractory treatment for NSCLC. Dacomitinib has not been approved by any regulatory agency.
Photo: Bigstock
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
